exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087748 RNA Name: hsa-miR-1321 RNA Type: miRNA Chromosome: chrX Starnd: + Coordinate: Start Site(bp): 85835832 End Site(bp): 85835849 External Links: hsa-miR-1321

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand DDAH1 chr1 85318481 85578363 - WASF2 chr1 27404230 27490167 - KDM5C chrX 53191321 53225422 - C19orf47 chr19 40319536 40348527 - UBE2Q1 chr1 154548577 154559028 - KLC2 chr11 66257294 66267860 + CBFA2T3 chr16 88874858 88977207 - ENSA chr1 150600851 150629612 - ZDHHC9 chrX 129803288 129843909 - MKNK2 chr19 2037465 2051244 - AKIRIN1 chr1 38991276 39006059 + NRF1 chr7 129611720 129757082 + REEP4 chr8 22138020 22141951 - BCL7A chr12 122019422 122062044 + CBX5 chr12 54230942 54280133 - SOX13 chr1 204073115 204127743 + LENG8 chr19 54448887 54462037 + CCND3 chr6 41934933 42050357 - STK35 chr20 2101827 2177038 + GPI chr19 34359480 34402413 + RCOR1 chr14 102592649 102730561 + ONECUT2 chr18 57435374 57491298 + SPTBN2 chr11 66685248 66729226 - WSB2 chr12 118032694 118062430 - ARID1A chr1 26693236 26782104 + HMGA1 chr6 34236873 34246231 + RARA chr17 40309180 40357643 + TP53 chr17 7661779 7687550 - TPP1 chr11 6612768 6619448 - SCD chr10 100347233 100364826 + miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC022167.2 chr16 8848105 8860456 + AC069281.2 chr7 100572232 100578700 - AC124068.2 chr15 89335053 89336161 + AP000233.2 chr21 25095022 25103670 + HCG18 chr6 30286690 30327382 - KCNQ1OT1 chr11 2608328 2699994 - MALAT1 chr11 65497688 65506516 + MIR22HG chr17 1711493 1717174 - NEAT1 chr11 65422774 65445540 + OIP5-AS1 chr15 41283990 41309737 + TYMSOS chr18 630886 658340 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.